Prognostic factors in patients with gemcitabine-refractory pancreatic cancer (Q45233598)

11 December 2017

Prognostic factors in patients with gemcitabine-refractory pancreatic cancer (English)

1 reference

11 December 2017

Kohei Nakachi

1

1 reference

11 December 2017

Junji Furuse

2

1 reference

11 December 2017

Hiroshi Ishii

3

1 reference

11 December 2017

Ei-ichiro Suzuki

4

1 reference

11 December 2017

Masahiro Yoshino

5

1 reference

11 December 2017

1 February 2007

1 reference

Japanese Journal of Clinical Oncology

11 December 2017

1 reference

11 December 2017

37

1 reference

11 December 2017

2

1 reference

11 December 2017

114-120

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

11 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Prognostic factors in the palliation of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYL144

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYL144

1 reference

11 December 2017

1 reference